Lilly's diabetes and obesity leader to retire in broader leadership shuffle as CSO Dan Skovronsky takes on immunology role
As Eli Lilly anticipates an FDA weight loss approval for its in-demand diabetes drug Mounjaro by year’s end, the drugmaker’s leader of those two areas will retire and be replaced by its immunology head.
Mike Mason, president of Lilly Diabetes and Obesity, will depart at the end of December after a 34-year career at the Indianapolis-based Big Pharma, per a Wednesday morning announcement. Lilly USA president and immunology president Patrik Jonsson, another three-decade veteran of the company, will take Mason’s place on Jan. 1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.